Generate Biomedicines, Inc.

GENB

GENBGenerate Biomedicines, Inc. US flag

NASDAQ Global Market

11.97

USD

-1.00

- -

1.53BMarket Cap

Income Statement (USD)

API Chat

	2024 Y	2025 Y
Sales/Revenue/Turnover	20	32
+ Sales & Services Revenue	20	32
- Cost of Revenue	- -	- -
+ Cost of Goods & Services	- -	- -
Gross Profit	- -	- -
+ Other Operating Income	-20	-32
- Operating Expenses	217	267
+ Selling, General & Admin	42	42
+ Research & Development	175	225
+ Other Operating Expense	- -	- -
Operating Income (Loss)	-197	-235
- Non-Operating (Income) Loss	-16	-12
+ Interest Expense, Net	-16	-13
+ Interest Expense	2	1
- Interest Income	18	14
+ Other Non-Op (Income) Loss	- -	- -
Pretax Income	-181	-223
- Income Tax Expense (Benefit)	- -	- -
- (Income) Loss from Affiliates	- -	- -
Income (Loss) from Cont Ops	-181	-223
- Net Extraordinary Losses (Gains)	-15	-40
+ Discontinued Operations	- -	- -
+ Extraord. & Accounting Changes	-15	-40
Income (Loss) Incl. MI	-166	-183
- Minority Interest	8	20
Net Income, GAAP	-174	-203
- Preferred Dividends	40	46
- Other Adjustments	- -	- -
Net Income Avail to Common, GAAP	-214	-250
EBIT	-197	-235
EBITDA	-182	-222
EBITDA Margin (%)	-887.58	-695.72
EBITA	-197	-235
Gross Margin (%)	100	100
Operating Margin (%)	-962.6	-737.04
Profit Margin (%)	-849.36	-636.99
Sales per Employee	- -	- -
Dividend per Share	- -	- -
Depreciation Expense	15	13
Basic Weighted Avg Shares	102	102
Basic EPS, GAAP	-2.09	-2.44
Basic EPS from Cont Ops	-1.77	-2.18
Diluted Weighted Avg Shares	102	102
Diluted EPS, GAAP	-2.09	-2.44
Diluted EPS from Cont Ops	-1.77	-2.18

Balance Sheet (USD)

API Chat

	2024 Y	2025 Y
Total Current Assets	407	234
+ Cash, Cash Equivalents & STI	394	221
+ Cash & Cash Equivalents	176	122
+ ST Investments	217	100
+ Accounts & Notes Receiv	- -	- -
+ Accounts Receivable, Net	- -	- -
+ Notes Receivable, Net	- -	- -
+ Loans Receivable, Net	- -	- -
+ Other Receivable, Net	- -	- -
+ Inventories	- -	- -
+ Raw Materials	- -	- -
+ Work In Process	- -	- -
+ Finished Goods	- -	- -
+ Inventory Adjustments	- -	- -
+ Other Inventory	- -	- -
+ Other ST Assets	14	13
+ Misc ST Assets	- -	- -
+ Prepaid Expenses	- -	- -
+ ST Derivative & Hedging Assets	- -	- -
+ ST Assets Held-for-Sale	- -	- -
+ ST Deferred Tax Assets	- -	- -
Total Noncurrent Assets	111	96
+ Property, Plant & Equip, Net	101	89
+ Property, Plant & Equip	136	137
- Accumulated Depreciation	35	48
+ LT Investments & Receivables	- -	- -
+ LT Investments	- -	- -
+ LT Receivables	- -	- -
+ Other LT Assets	10	7
+ Total Intangible Assets	- -	- -
+ Goodwill	- -	- -
+ Other Intangible Assets	- -	- -
+ LT Deferred Tax Assets	- -	- -
+ LT Derivative & Hedging Assets	- -	- -
+ Misc LT Assets	10	7
Total Assets	518	330
+ Payables & Accruals	12	30
+ Accounts Payable	6	4
+ Accrued Taxes	- -	- -
+ Interest & Dividends Payable	- -	- -
+ Other Payables & Accruals	6	26
+ ST Debt	17	15
+ ST Borrowings	- -	- -
+ ST Finance Leases	17	15
+ Other ST Liabilities	58	38
+ Deferred Revenue	42	21
+ Derivatives & Hedging	- -	- -
+ Deferred Tax Liabilities	- -	- -
+ Misc ST Liabilities	16	16
Total Current Liabilities	87	82
+ LT Debt	60	54
+ LT Borrowings	- -	- -
+ LT Finance Leases	60	54
+ Other LT Liabilities	806	818
+ Accrued Liabilities	15	5
+ Pension Liabilities	- -	- -
+ Deferred Revenue	- -	- -
+ Deferred Tax Liabilities	- -	- -
+ Derivatives & Hedging	- -	- -
+ Misc LT Liabilities	791	813
Total Noncurrent Liabilities	867	871
Total Liabilities	953	953
+ Preferred Equity and Hybrid Capital	- -	- -
+ Share Capital & APIC	39	60
+ Common Stock	- -	- -
+ Additional Paid in Capital	38	60
- Treasury Stock	- -	- -
+ Retained Earnings	-473	-676
+ Other Equity	- -	- -
Equity Before Minority Interest	-435	-616
+ Minority/Non Controlling Interest	-1	-7
Total Equity	-435	-623
Total Liabilities & Equity	518	330
Shares Outstanding	127	127
Number of Employees	- -	- -
Capital Leases - Total	77	69
Net Debt	-176	-122
Net Debt to Equity	40.51	19.52
Tangible Common Equity Ratio	-83.95	-188.74
Current Ratio	4.7	2.85
Cash Conversion Cycle	- -	- -

Cash Flow Statement (USD)

API Chat

	2024 Y	2025 Y
+ Net Income	-181	-223
+ Depreciation & Amortization	15	13
+ Non-Cash Items	20	24
+ Stock-Based Compensation	19	21
+ Deferred Income Taxes	- -	- -
+ Asset Impairment Charge	- -	- -
+ Other Non-Cash Adj	1	3
+ Chg in Non-Cash Work Cap	28	-15
+ (Inc) Dec in Accts Receiv	- -	- -
+ (Inc) Dec in Inventories	- -	- -
+ (Inc) Dec in Prepaid Assets	-5	- -
+ Inc (Dec) in Accts Payable	8	15
+ Inc (Dec) in Other	26	-30
+ Net Cash From Disc Ops	- -	- -
Cash from Operating Activities	-118	-201
+ Change in Fixed & Intang	- -	- -
+ Disp in Fixed & Intang	- -	- -
+ Disp of Fixed Prod Assets	- -	- -
+ Disp of Intangible Assets	- -	- -
+ Acq of Fixed & Intang	-3	-4
+ Acq of Fixed Prod Assets	-3	-4
+ Acq of Intangible Assets	- -	- -
+ Cash (Repurchase) of Equity	- -	- -
+ Increase in Capital Stock	- -	- -
+ Decrease in Capital Stock	- -	- -
+ Net Change in LT Investment	-54	120
+ Dec in LT Investment	229	285
+ Inc in LT Investment	-283	-165
+ Net Cash From Acq & Div	- -	- -
+ Cash from Divestitures	- -	- -
+ Cash for Acq of Subs	- -	- -
+ Cash for JVs	- -	- -
+ Other Investing Activities	- -	- -
+ Net Cash From Disc Ops	- -	- -
Cash from Investing Activities	-58	117
+ Dividends Paid	- -	- -
+ Net Cash From Debt	-11	-8
+ Cash From Debt	- -	- -
+ Repayments of Debt	-11	-8
+ Other Financing Activities	102	36
+ Net Cash From Disc Ops	- -	- -
Cash from Financing Activities	91	28
Effect of Foreign Exchange Rates	- -	- -
Net Changes in Cash	-84	-56
EBITDA	-182	-222
EBITDA Margin (%)	-887.58	-695.72
Free Cash Flow	-121	-204
Net Cash Paid for Acquisitions	- -	- -
Free Cash Flow to Firm	- -	- -
Free Cash Flow to Equity	- -	-259
Free Cash Flow per Basic Share	-1.18	-2
Price/Free Cash Flow	- -	- -
Cash Flow to Net Income	0.68	0.99
Capital Expenditures	-3	-4